Nishigami Kohei, Kawami Hiroyuki, Yamaguchi Tomohito, Yamaguchi Kiyotaka, Kato Seiichi
Division of Digestive and General Surgery, Hokuto Hospital.
Gan To Kagaku Ryoho. 2009 Oct;36(10):1765-8.
The case was a 69-year-old man with liver metastasis who had relapsed after the resection of rectal cancer. We treated the patient with FOLFIRI+bevacizumab(BV)after the failure of S-1+CPT-11, radiation, UFT/LV, FOLFOX and FOLFIRI regimen. The tumor marker level and accumulation of FDG-PET were rapidly decreased after initiating FOLFIRI+BV. There was no serious adverse event, and a remarkable improvement of QOL was observed. This case suggests that the BV combination regimen is useful even after the failure of FOLFOX and FOLFIRI regimen.
该病例为一名69岁的男性，患有肝转移，在直肠癌切除术后复发。在S-1+CPT-11、放疗、UFT/LV、FOLFOX和FOLFIRI方案治疗失败后，我们采用FOLFIRI+贝伐单抗（BV）对该患者进行治疗。开始使用FOLFIRI+BV后，肿瘤标志物水平和FDG-PET的摄取迅速下降。未出现严重不良事件，且观察到生活质量有显著改善。该病例表明，即使在FOLFOX和FOLFIRI方案治疗失败后，BV联合方案仍有效。
